Transcarent has rolled out a bundled payment model for cancer therapies, a new initiative designed to help employers manage the high costs associated with advanced treatments. The program targets bispecific T-cell engager and CAR T therapies, aiming to offer greater financial predictability for companies while connecting patients with leading oncology providers.
Connecting Patients to Specialized Care
The model expands Transcarent’s existing Centers of Excellence network, linking members with care at both academic medical centers and high-quality community sites. By integrating these two tiers of care, the initiative ensures that patients can begin treatment at a major research hospital and, when appropriate, transition to a community facility that offers comparable clinical expertise. This continuity is reinforced by certified oncology nurse navigators who coordinate appointments, manage referrals, and keep clinical information flowing smoothly between institutions, thereby reducing the administrative friction that often accompanies multi‑site treatment plans.
Members receive support throughout their treatment journey through certified oncology nurse navigators who assist them as they move between different care settings. The company claims the approach can generate potential savings of up to $150,000.
“Advanced cancer therapies are changing what’s possible for patients, but they’re also creating new challenges for employers trying to manage costs and access,” said Snezana Mahon, Transcarent’s president, in a statement. “This model gives employers more predictable costs while helping Members receive expert care closer to home without sacrificing quality.”
Healthcare navigation is a central component of the new offering. Certified oncology nurse navigators guide members through the care process, providing an added layer of support as they receive treatment. The company notes that this combination of payment structure and navigation services helps streamline the experience for patients facing complex medical needs.
Related: Americans Want AI Disclosure in Healthcare Survey Says
According to Karen Knudsen, Ph.D., the company’s Cancer Care Advisory Board Chair, expanding access to advanced therapies in high-quality community settings is a critical step. “This model can reduce barriers to treatment while improving the experience for people and their families facing some of the most complex cancers,” Knudsen said.
Transcarent is continuing to build out its platform capabilities. The launch follows a January expansion of its WayFinding platform, which added agentic AI capabilities like voice AI scheduling and advanced symptom‑checking. The cancer‑care initiative adds another layer to the company’s existing navigation tools, reinforcing its focus on supporting members through long treatment journeys.
The WayFinding platform’s recent AI enhancements play a complementary role in the cancer‑care offering. Voice‑enabled AI scheduling streamlines the appointment‑booking process, allowing members to secure time with specialists without handling traditional phone trees. Advanced symptom‑checking tools, powered by the same AI engine, enable patients to report side effects in real time, triggering proactive outreach from nurse navigators and potentially averting emergency interventions.
By aligning payment certainty, provider quality, and navigational support, Transcarent’s bundled payment model creates a cohesive ecosystem that addresses both the economic and experiential challenges of modern oncology care. Employers gain a clearer view of their investment in employee health, while members benefit from coordinated, high‑caliber treatment pathways that are designed to minimize disruption to their daily lives.
